DNA that is shed by dead tumor cells into the blood, termed circulating tumor DNA (ctDNA), is a rich resource that could potentially be used for cancer diagnostics and monitoring. A new study describes a sequencing-based method that improves upon the sensitivity and specificity achieved by past techniques for detecting ctDNA and that can be used for monitoring of disease burden in patients with non–small-cell lung cancer (pages 548–554).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients
Scientific Reports Open Access 07 April 2021
-
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
BMC Cancer Open Access 16 April 2020
-
Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer
Breast Cancer Research Open Access 19 December 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sidransky, D. Nat. Rev. Cancer 2, 210–219 (2002).
Bettegowda, C. et al. Sci. Transl. Med. 6, 224ra24 (2014).
Newman, A.M. et al. Nat. Med. 20, 548–554 (2014).
Schmitt, M.W. et al. Proc. Natl. Acad. Sci. USA 109, 14508–14513 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.T.S. and J.W.G. have received royalties on intellectual property licensed to Cepheid, and J.W.G. is a consultant for and research grantee of Cepheid.
Rights and permissions
About this article
Cite this article
Spellman, P., Gray, J. Detecting cancer by monitoring circulating tumor DNA. Nat Med 20, 474–475 (2014). https://doi.org/10.1038/nm.3564
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3564
This article is cited by
-
Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients
Scientific Reports (2021)
-
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
BMC Cancer (2020)
-
Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer
Breast Cancer Research (2019)
-
Advanced methods for microRNA biosensing: a problem-solving perspective
Analytical and Bioanalytical Chemistry (2019)
-
Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device
Nature Protocols (2018)